Drug Profile
Research programme: central nervous system therapeutics - ArmaGen
Alternative Names: AGT-120; AGT-185; AGT-3100; Rett fusion protein - ArmaGen; Rett syndrome therapeutic - ArmaGenLatest Information Update: 23 Apr 2020
Price :
$50
*
At a glance
- Originator ArmaGen Technologies
- Class Antibodies; Enzymes; Immunoglobulin fusion proteins
- Mechanism of Action Acetylcholinesterase inhibitors; Protein replacements; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain disorders; Major depressive disorder; Poisoning; Rett syndrome; Spinal cord injuries
Most Recent Events
- 21 Apr 2020 ArmaGen Technologies has been acquired by JCR Pharmaceuticals
- 13 Sep 2019 Discontinued for Rett syndrome in USA (unspecified route) (ArmaGen pipeline, September 2019)
- 10 Sep 2019 Discontinued - Preclinical for Brain disorders in USA (IV) (ArmaGen pipeline, September 2019)